Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Halozyme Therapeutics
HALO
5
DOMINOS PIZZA ENTERPRISES LIMITED UNSP ADR EACH REPR 0.5 ORD SHS
DMZPY
US Stock MarketDetailed Quotes
ADAG Adagene
- 1.525
- +0.115+8.16%
Trading Apr 30 13:42 ET
71.84MMarket Cap-2.07P/E (TTM)
1.525High1.435Low15.23KVolume1.450Open1.410Pre Close22.28KTurnover0.11%Turnover RatioLossP/E (Static)47.11MShares3.58152wk High1.42P/B20.88MFloat Cap1.32552wk Low--Dividend TTM13.69MShs Float31.830Historical High--Div YieldTTM6.38%Amplitude0.900Historical Low1.463Avg Price1Lot Size
Market Insights
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current
Moomoo News Global
Apr 28 18:10
Warren Buffett Stands Tall as U.S. Stocks Tumble: How the 'Oracle' Is Tackling Tariff Impacts
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call
Adagene Stock Forum
Adagene Announces Investigator Initiated Phase 2 Trial for Neoadjuvant Muzastotug (ADG126) in Colorectal Cancer
2 minutes ago, 5:00 AM PST
Via GlobeNewswire
ADAG
Share
- Trial to begin enrolling in April; expected primary completion in mid-2027 -
- Primary study endpoint of rate of major pathological response -
SAN DIEGO and SUZHOU, China, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of no...
Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium
Monday, 27th January at 7:00 am
Muzastotug (ADG126), an Anti-CTLA-4 SAFEbody® in Combination with pembrolizumab showed 33% overall response rate in microsatellite stable colorectal cancer
Four confirmed partial responses out of twelve patients with 20 mg/kg loading dose followed by 10 mg/kg Q3W + ...
New data will include initial results from the 20 mg/kg loading dose followed by 10 mg/kg Q3W in combination with pembrolizumab.
Adagene to Announce Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium
Tuesday, 21st January at 5:00 pm
SAN DIEGO and SUZHOU, China, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced it will share updated clinical data from ADG126 in micro...
Adagene to Host Virtual KOL Event to Discuss Anti-CTLA-4 SAFEbody® ADG126 in Advanced/Metastatic Microsatellite-Stable (MSS) Colorectal Cancer (CRC) on January 25, 2025
Tuesday, 14th January at 8:00 am
SAN DIEGO and SUZHOU, China, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced it will host a virtual key opinion leader (KOL) event on Saturday,...
Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
Adagene Inc. (Nasdaq: ADAG) has announced upcoming poster presentations at the SITC 39th Annual Meeting in Houston, scheduled for November 6-10, 2024. The presentations will focus on Muzastotug (ADG126), a masked anti-CTLA-4 SAFEbody®.
Two posters will be presented on November 9:
Abstract 506: Comparing the ...
Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
Rhea-AI Impact(Moderate)Rhea-AI Sentiment(Very Positive)TagsRhea-AI SummaryPositiveDoubled confirmed partial responses to four in MSS CRC patients without liver and peritoneal metastases24% overall response rate (ORR) with...
No comment yet